These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 35400177)
1. Bone Penetration of Cycloserine in Osteoarticular Tuberculosis Patients of China. Zhang T; Yu X; Wen S; Xue Y; Xiao H; Ren R; Wang F; Dong L; Qin S; Huang H Antimicrob Agents Chemother; 2022 May; 66(5):e0222421. PubMed ID: 35400177 [TBL] [Abstract][Full Text] [Related]
2. Bone penetration of linezolid in osteoarticular tuberculosis patients of China. Wen S; Zhang T; Yu X; Dong W; Lan T; Fan J; Xue Y; Wang F; Dong L; Qin S; Huang H Int J Infect Dis; 2021 Feb; 103():364-369. PubMed ID: 33278623 [TBL] [Abstract][Full Text] [Related]
3. Validation of Cycloserine Efficacy in Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Beijing, China. Yu X; Zeng X; Shi W; Hu Y; Nie W; Chu N; Huang H Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311073 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring of cycloserine and linezolid during anti-tuberculosis treatment in Beijing, China. Zhu H; Guo SC; Liu ZQ; Wang B; Fu L; Chu NH; Lu Y Int J Tuberc Lung Dis; 2018 Aug; 22(8):931-936. PubMed ID: 29991404 [TBL] [Abstract][Full Text] [Related]
5. Neuropsychiatric reactions induced by cycloserine in the treatment of multidrug-resistant tuberculosis: what an Indian female patient tells us. Intini E; Kishore G; Richeldi L; Udwadia ZF BMJ Case Rep; 2019 Dec; 12(12):. PubMed ID: 31806629 [TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for treatment success in patients with multidrug-resistant tuberculosis in China. Fan YM; Ding SP; Bao ZJ; Wu LM; Zhen LB; Xia Q; Zhu M Int J Tuberc Lung Dis; 2018 Mar; 22(3):300-305. PubMed ID: 29471908 [TBL] [Abstract][Full Text] [Related]
7. XDR TB presenting as a transphyseal lytic lesion in the proximal tibia. Aggarwal R; Purohit S; Nemade P; Panjwani T BMJ Case Rep; 2015 Aug; 2015():. PubMed ID: 26264953 [No Abstract] [Full Text] [Related]
8. A selective and sensitive high performance liquid chromatography assay for the determination of cycloserine in human plasma. Hemanth Kumar AK; Polisetty AK; Sudha V; Vijayakumar A; Ramachandran G Indian J Tuberc; 2018 Apr; 65(2):118-123. PubMed ID: 29579424 [TBL] [Abstract][Full Text] [Related]
9. Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis. Court R; Wiesner L; Stewart A; de Vries N; Harding J; Maartens G; Gumbo T; McIlleron H Int J Tuberc Lung Dis; 2018 Jan; 22(1):30-33. PubMed ID: 29297422 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. Prasad R; Verma SK; Sahai S; Kumar S; Jain A Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675 [TBL] [Abstract][Full Text] [Related]
11. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125 [TBL] [Abstract][Full Text] [Related]
12. Drug treatment of multidrug-resistant osteoarticular tuberculosis: a systematic literature review. Suárez-García I; Noguerado A Int J Infect Dis; 2012 Nov; 16(11):e774-8. PubMed ID: 22940279 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis. van der Galiën R; Boveneind-Vrubleuskaya NV; Peloquin C; Skrahina A; Touw DJ; Alffenaar JC Clin Pharmacokinet; 2020 Jul; 59(7):899-910. PubMed ID: 31981103 [TBL] [Abstract][Full Text] [Related]
14. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. Park S; Jo KW; Lee SD; Kim WS; Shim TS Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041 [TBL] [Abstract][Full Text] [Related]
15. Serum concentrations of cycloserine and outcome of multidrug-resistant tuberculosis in Northern Taiwan. Hung WY; Yu MC; Chiang YC; Chang JH; Chiang CY; Chang CC; Chuang HC; Bai KJ Int J Tuberc Lung Dis; 2014 May; 18(5):601-6. PubMed ID: 24903799 [TBL] [Abstract][Full Text] [Related]
16. Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis. van der Laan LE; Garcia-Prats AJ; McIlleron H; Abdelwahab MT; Winckler JL; Draper HR; Wiesner L; Schaaf HS; Hesseling AC; Denti P Antimicrob Agents Chemother; 2023 Dec; 67(12):e0061123. PubMed ID: 37971239 [TBL] [Abstract][Full Text] [Related]
17. Newer knowledge of chemotherapy in the treatment of tuberculosis of bones and joints. Friedman B; Kapur VN Clin Orthop Relat Res; 1973; (97):5-15. PubMed ID: 4359522 [No Abstract] [Full Text] [Related]
19. Profile of osteoarticular tuberculosis in children. Shah I; Dani S; Shetty NS; Mehta R; Nene A Indian J Tuberc; 2020 Jan; 67(1):43-45. PubMed ID: 32192616 [TBL] [Abstract][Full Text] [Related]
20. Treatment Outcomes and Adverse Drug Effects of Ethambutol, Cycloserine, and Terizidone for the Treatment of Multidrug-Resistant Tuberculosis in South Africa. van der Walt ML; Shean K; Becker P; Keddy KH; Lancaster J Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046491 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]